Literature DB >> 22424234

Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.

Daniel E Goldberg1, Robert F Siliciano, William R Jacobs.   

Abstract

Although caused by vastly different pathogens, the world's three most serious infectious diseases, tuberculosis, malaria, and HIV-1 infection, share the common problem of drug resistance. The pace of drug development has been very slow for tuberculosis and malaria and rapid for HIV-1. But for each disease, resistance to most drugs has appeared quickly after the introduction of the drug. Learning how to manage and prevent resistance is a major medical challenge that requires an understanding of the evolutionary dynamics of each pathogen. This Review summarizes the similarities and differences in the evolution of drug resistance for these three pathogens.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22424234      PMCID: PMC3322542          DOI: 10.1016/j.cell.2012.02.021

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  110 in total

1.  HIV drug resistance.

Authors:  François Clavel; Allan J Hance
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

Review 2.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

3.  Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum.

Authors:  Roland A Cooper; Michael T Ferdig; Xin-Zhuan Su; Lyann M B Ursos; Jianbing Mu; Takashi Nomura; Hisashi Fujioka; David A Fidock; Paul D Roepe; Thomas E Wellems
Journal:  Mol Pharmacol       Date:  2002-01       Impact factor: 4.436

Review 4.  Challenges and opportunities in developing novel drugs for TB.

Authors:  Takushi Kaneko; Christopher Cooper; Khisimuzi Mdluli
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 5.  Drug-resistant malaria.

Authors:  John E Hyde
Journal:  Trends Parasitol       Date:  2005-09-02

Review 6.  The ABCs of multidrug resistance in malaria.

Authors:  Jan B Koenderink; Reginald A Kavishe; Sanna R Rijpma; Frans G M Russel
Journal:  Trends Parasitol       Date:  2010-06-11

7.  Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.

Authors:  Kristin N Adams; Kevin Takaki; Lynn E Connolly; Heather Wiedenhoft; Kathryn Winglee; Olivier Humbert; Paul H Edelstein; Christine L Cosma; Lalita Ramakrishnan
Journal:  Cell       Date:  2011-03-03       Impact factor: 41.582

8.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Authors:  S M Hammer; K E Squires; M D Hughes; J M Grimes; L M Demeter; J S Currier; J J Eron; J E Feinberg; H H Balfour; L R Deyton; J A Chodakewitz; M A Fischl
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

Review 9.  Improvements in antiretroviral therapy outcomes over calendar time.

Authors:  Mark A Boyd
Journal:  Curr Opin HIV AIDS       Date:  2009-05       Impact factor: 4.283

10.  The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug.

Authors:  R M MCCUNE; W MCDERMOTT; R TOMPSETT
Journal:  J Exp Med       Date:  1956-11-01       Impact factor: 14.307

View more
  64 in total

1.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance.

Authors:  Hongtai Zhang; Dongfang Li; Lili Zhao; Joy Fleming; Nan Lin; Ting Wang; Zhangyi Liu; Chuanyou Li; Nicholas Galwey; Jiaoyu Deng; Ying Zhou; Yuanfang Zhu; Yunrong Gao; Tong Wang; Shihua Wang; Yufen Huang; Ming Wang; Qiu Zhong; Lin Zhou; Tao Chen; Jie Zhou; Ruifu Yang; Guofeng Zhu; Haiying Hang; Jia Zhang; Fabin Li; Kanglin Wan; Jun Wang; Xian-En Zhang; Lijun Bi
Journal:  Nat Genet       Date:  2013-09-01       Impact factor: 38.330

Review 2.  Three-dimensional structures in the design of therapeutics targeting parasitic protozoa: reflections on the past, present and future.

Authors:  Wim G J Hol
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-04-16       Impact factor: 1.056

Review 3.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

Review 4.  Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis.

Authors:  N P Mnyambwa; D-J Kim; E S Ngadaya; R Kazwala; P Petrucka; S G Mfinanga
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-07       Impact factor: 3.267

Review 5.  Evolutionary scalpels for dissecting tumor ecosystems.

Authors:  Daniel I S Rosenbloom; Pablo G Camara; Tim Chu; Raul Rabadan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2016-12-05       Impact factor: 10.680

6.  Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5.

Authors:  Massimiliano Secchi; Lia Vassena; Sébastien Morin; Dominique Schols; Luca Vangelista
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

7.  Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo.

Authors:  Eva Maria Novoa; Noelia Camacho; Anna Tor; Barrie Wilkinson; Steven Moss; Patricia Marín-García; Isabel G Azcárate; José M Bautista; Adam C Mirando; Christopher S Francklyn; Sònia Varon; Miriam Royo; Alfred Cortés; Lluís Ribas de Pouplana
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

8.  Highly heterogeneous mutation rates in the hepatitis C virus genome.

Authors:  Ron Geller; Úrsula Estada; Joan B Peris; Iván Andreu; Juan-Vicente Bou; Raquel Garijo; José M Cuevas; Rosario Sabariegos; Antonio Mas; Rafael Sanjuán
Journal:  Nat Microbiol       Date:  2016-04-18       Impact factor: 17.745

9.  Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.

Authors:  Sreekanth Kokkonda; Xiaoyi Deng; Karen L White; Farah El Mazouni; John White; David M Shackleford; Kasiram Katneni; Francis C K Chiu; Helena Barker; Jenna McLaren; Elly Crighton; Gong Chen; Inigo Angulo-Barturen; Maria Belen Jimenez-Diaz; Santiago Ferrer; Leticia Huertas-Valentin; Maria Santos Martinez-Martinez; Maria Jose Lafuente-Monasterio; Rajesh Chittimalla; Shatrughan P Shahi; Sergio Wittlin; David Waterson; Jeremy N Burrows; Dave Matthews; Diana Tomchick; Pradipsinh K Rathod; Michael J Palmer; Susan A Charman; Margaret A Phillips
Journal:  J Med Chem       Date:  2020-04-16       Impact factor: 7.446

10.  The Mycobacterium tuberculosis outer membrane channel protein CpnT confers susceptibility to toxic molecules.

Authors:  Olga Danilchanka; David Pires; Elsa Anes; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.